Biochemical markers (without markers of infection) of the risk of preterm delivery. Implications for clinical practice.
BACKGROUND
New biochemical markers for the risk of spontaneous preterm birth (SPB) give a more precise and earlier diagnosis than the usual ones. We reviewed the data about the principal markers.


RESULTS
Using studies with good methodology and a large number of subjects, we observe that the predictive value of these new markers is somewhat higher than those of the usual markers. Fetal fibro-nectin (FNf) and cervical ultrasound undeniably improve the identification of patients at risk of preterm birth, both in the general population and in these threatened preterm delivery. However no management has yet been demonstrated efficacious, especially in a general population so any recommendations for their systematic utilisation is premature. Other biochemical markers (salivary estriol, serum CRH, etc.) are still under assessment and should not be used outside research protocols.


CONCLUSIONS
It is appropriate to integrate either FNf or cervical ultrasound into daily clinical practice for patients with signs of preterm labor. These new indicators are of special use when the diagnosis is uncertain with the standard markers (uterine contractions, digital examination). Among these patients, they should reduce the number of hospitalizations and of useless treatments, because of their good negative predictive value. At the same time, for patients poorly 'labeled' by the clinical examination, they should allow the application of intensive management (intravenous tocolysis, corticoids, in utero transfers).


CONCLUSIONS
Future studies should evaluate these tests in everyday practice. The objective is not to predict preterm birth but to prevent either it or its negative consequences. This goal will be met when we have an effective treatment, without associated adverse effects, to offer patients after a positive test result.
Goffinet
F
F
Department of Obstetrics and Gynecology, Maternity Port-Royal, Cochin-Saint Vincent-de-Paul Hospital, 123 Bd de Port-Royal, 75014, Paris, France. goffinet@cochin.inserm.fr
Maillard
F
F
Fulla
Y
Y
Cabrol
D
D
D015415:Biomarkers / Q000032:analysis*; D003346:Corticotropin-Releasing Hormone / Q000097:blood; D004964:Estriol / Q000032:analysis / Q000097:blood; D005260:Female; D005353:Fibronectins; D006023:Glycoproteins / Q000032:analysis; D006801:Humans; D007752:Obstetric Labor, Premature / Q000175:diagnosis*; D011247:Pregnancy; D012307:Risk Factors; D012463:Saliva / Q000737:chemistry
D015415:Biomarkers; C403421:FFN protein, human; D005353:Fibronectins; D006023:Glycoproteins; D003346:Corticotropin-Releasing Hormone; D004964:Estriol